Tofacitinib citrate is under clinical development by CAGE Bio and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tofacitinib citrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tofacitinib citrate overview

Tofacitinib citrate is under development for the treatment of atopic dermatitis. It is administered through topical route as ointment. It acts by targeting Janus kinase (JAK).

CAGE Bio overview

CAGE Bio is a pharmaceutical drug development and clinical research company. The company specializes in drug development for various therapeutic areas such as dermatology, inflammation, and immunology. Its service offering includes clinical trials, research and development, and drug discovery programs. The company delivers a wide range of materials including small molecules, peptides, proteins and nucleic acids. It uses Ionic Liquid (IL) platform to improve tissue specific delivey in multiple modalities and diseases, immunodermatological diseases. CAGE Bio is headquartered in San Carlos, California, the US.

For a complete picture of Tofacitinib citrate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.